Self-Management Interventions After an ICD Shock

Sponsor
University of Washington (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06037785
Collaborator
East Carolina University (Other), National Institute of Nursing Research (NINR) (NIH)
60
1
2
20
3

Study Details

Study Description

Brief Summary

This study, "Biobehavioral Intervention to Reduce PTSD Symptoms After an ICD Shock," addresses a critical need in cardiology care by describing the feasibility and acceptability of a timely, highly promising, electronically-delivered intervention for patients who have recently received an ICD delivered shock. The study intervention and outcomes are designed to reduce anxiety, enhance return to activities of daily living (ADLs), and prevent the development of severe distress and post-traumatic stress disorder (PTSD), and ultimately promote quality of life. The study is a two-arm, embedded mixed methods, randomized trial (N=60, 30/group). The purpose is to determine feasibility and potential effects of a self-management intervention (SPSM) plus usual care (UC) compared to UC alone, delivered during the critical 1 month period after an ICD shock when distress is high. The intervention will be delivered over 1 month following an ICD shock; a 6-month follow-up will be used to assess the sustainability of intervention effects and determine if the incidence of PTSD is reduced. SPSM includes: 1) training in heart rate (HR) self-monitoring; and 2) individualized learning through 4 self-paced, web-based modules. The study interventions are delivered at a crucial time, closely after an ICD shock when stress is high, but PTSD has not yet developed. The specific aims are to: 1) examine the effects of the SPSM intervention plus UC vs. UC alone on the primary outcome of ICD shock anxiety at 1 and 6 months post-shock event, 2) describe the impact of SPSM plus UC compared to UC alone on the secondary outcomes of total daily physical activity, depression, PTSD symptoms, QOL, salivary cortisol levels, and self-efficacy and outcome expectations at 1 and 6 months post-shock event, and 3) assess feasibility, acceptability, and safety of the SPSM intervention, SDOH will be used to describe differential responses to the SPSM intervention. This study fills a significant gap in the care of patients with an ICD, through the systematic testing of a brief, novel and cost-effective intervention that provides the knowledge and skills to improve quality of life. Study findings will be used to design future larger RCTs to test intervention effectiveness for more diverse samples and settings.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Self-Paced Self-Management (SPSM)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Biobehavioral Intervention to Reduce PTSD After ICD Shock
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Jul 31, 2025
Anticipated Study Completion Date :
Jul 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: SPSM intervention

Heart rate self monitoring Online shock management modules

Behavioral: Self-Paced Self-Management (SPSM)
(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.

No Intervention: usual care

standard observation and post-ICD shock care at each clinic that includes ICD interrogations monitored in-person or via home monitor

Outcome Measures

Primary Outcome Measures

  1. ICD Shock anxiety [Baseline, 1, 6 months]

    Florida Shock Anxiety Scale: range 1-50, higher is higher anxiety.

Secondary Outcome Measures

  1. Total daily physical activity(steps/day) [Baseline, 1, 6 months]

    Step Watch Activity Monitor, 0-unlimited number of steps. Higher is more steps.

  2. Depression [Baseline, 1, 6 months]

    PHQ-9, 0-27. Higher is higher depression.

  3. PTSD Symptoms [Baseline, 1, 6 months]

    Post-traumatic Stress Disorder Checklist PCL-5, 0-80. Higher is higher PTSD symtpoms

  4. Quality of Life-Physical and Mental [Baseline, 1, 6 months]

    PROMIS Global v 2.0, 0-50. Higher is higher qol.

  5. Self-Efficacy Expectation [Baseline, 1, 6 months]

    Self-Efficacy Expectations-SE scale, 0-60, Higher is more self-efficacy

  6. Outcome expectation, 0-90. Higher is higher OE. [Baseline, 1, 6 months]

    OE Scale

  7. Salivary cortisol [Baseline, 1, 6 months]

    Cortisol in saliva, the range in humans varies. measured in pg/ml.

  8. Feasibility [6 months]

    Feasibility will be measured using patient recruitment and contact rates (reach within 1-3 days of shock, number screened, eligible & enrolled, proportion eligible vs agree to participate). Each of these variables creates a number for the total study.

  9. Acceptability [6 months]

    Acceptability of interventions and materials measured in terms of patient burden (time to complete questionnaires & data collection, ease in understanding, implementing the intervention). These are qualitative open ended answers to questions and do not produce a number.

  10. Safety [2 years]

    Safety: major adverse cardiac events, including mortality (all cause and cardiac). This is measured as yes or no.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. ICD implant for primary or secondary prevention of sudden cardiac arrest (SCA), 2) receipt of at least 1 ICD shock, appropriate or inappropriate, one week prior to enrollment; 3) able to read, speak and write English; 4) access to online resources and telephone for study duration.
Exclusion Criteria:
  1. current diagnosis of PTSD, schizophrenia or bipolar disorder; 2) Short BLESSED score >6 indicating cognitive dysfunction [73]; 3) age <18 years; 4) AUDIT-C score ≥4 for alcohol use [74]; and 5) regular non-medical use of illicit drugs

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Washington Seattle Washington United States 98195

Sponsors and Collaborators

  • University of Washington
  • East Carolina University
  • National Institute of Nursing Research (NINR)

Investigators

  • Principal Investigator: Cynthia M Dougherty, ARNP, PhD, University of Washington

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cynthia M. Dougherty, Adjunct Associate Professor: School of Medicine, University of Washington
ClinicalTrials.gov Identifier:
NCT06037785
Other Study ID Numbers:
  • STUDY00007840
  • 1R21NR020967-01
First Posted:
Sep 14, 2023
Last Update Posted:
Sep 14, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Cynthia M. Dougherty, Adjunct Associate Professor: School of Medicine, University of Washington
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2023